AbbVie agreed to pay $650 million up front to license RemeGen’s PD‑1×VEGF bispecific antibody outside greater China, entering a crowded bispecific oncology field with milestone potential into the billions. AbbVie framed the deal as accelerating its oncology pipeline in a modality that combines immune checkpoint and angiogenesis blockade. Separately, Novartis paid $165 million up front to license a SciNeuro preclinical amyloid‑targeting shuttle program aimed at improving brain delivery of Alzheimer's therapeutics; the arrangement includes up to $1.5 billion in downstream milestones and potential royalties. Both transactions underscore Big Pharma’s appetite for external innovation to acquire differentiated mechanisms and address delivery challenges in neuroscience and oncology.